Lon­za adds on small mol­e­cule fa­cil­i­ty at Visp site, adding new weight to its ex­pan­sion plans on the back of a big year

In De­cem­ber, Swiss CD­MO Lon­za promised to in­crease its over­all pro­duc­tion ca­pac­i­ty by 30% by the first half of 2022, and it planned to do so by ex­pand­ing bio­con­ju­ga­tion ca­pa­bil­i­ties at its Visp, Switzer­land fa­cil­i­ty. Now, it’s tak­ing that ex­pan­sion one step fur­ther and adding a 2,1528-square-foot small mol­e­cule com­plex at the same site.

The com­plex will in­clude a cus­tomer-ded­i­cat­ed man­u­fac­tur­ing line for an­ti­body-drug con­ju­gate (ADC) pay­load mol­e­cules, the first of its kind, ac­cord­ing to the com­pa­ny. Op­er­a­tions will be­gin in 2023, Lon­za said.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER